This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Otten, R. A.
Right arrow Articles by Folks, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Otten, R. A.
Right arrow Articles by Folks, T. M.

 Previous Article  |  Next Article 

Journal of Virology, October 2000, p. 9771-9775, Vol. 74, No. 20
0022-538X/00/$04.00+0

Efficacy of Postexposure Prophylaxis after Intravaginal Exposure of Pig-Tailed Macaques to a Human-Derived Retrovirus (Human Immunodeficiency Virus Type 2)

Ron A. Otten,1,* Dawn K. Smith,2 Debra R. Adams,1 Jennifer K. Pullium,1,3 Eddie Jackson,4 Caryn N. Kim,1 Harold Jaffe,1 Robert Janssen,2 Sal Butera,1 and Thomas M. Folks1

Division of AIDS, STD, and TB Laboratory Research1 and Scientific Resources Program,4 National Center for Infectious Diseases, and Division of HIV/AIDS Prevention, Surveillance, and Epidemiology, National Center for HIV, STD, and TB Prevention,2 Centers for Disease Control and Prevention, Atlanta, Georgia 30333, and Division of Animal Resources, Emory University, Atlanta, Georgia 303323

Received 23 March 2000/Accepted 14 July 2000

Postexposure prophylaxis (PEP) after intravaginal exposure to human immunodeficiency virus (HIV) was investigated using the HIV type 2 (HIV-2)/pig-tailed macaque transmission model. PEP for 28 days with the reverse transcriptase inhibitor (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA; tenofovir) was initiated 12 to 72 h following HIV-2 exposure. Systemic infection was not evident in the 12- and 36-h groups, as defined by plasma viremia, cell-associated provirus, antibody responses, and lymph node virus. Breakthrough infection in the 72-h group was detected at week 16 post-virus exposure. These results demonstrate for the first time using a vaginal transmission model that early intervention after high-risk sexual exposures may prevent infection.

* Corresponding author. Mailing address: Mailstop G-19, HARB, DASTLR, NCID, CDC, 1600 Clifton Rd., Atlanta, GA 30333. Phone: (404) 639-1018. Fax: (404) 639-1174. E-mail: rxol{at}cdc.gov.

Journal of Virology, October 2000, p. 9771-9775, Vol. 74, No. 20
0022-538X/00/$04.00+0


This article has been cited by other articles:

  • Landovitz, R. J., Currier, J. S. (2009). Postexposure Prophylaxis for HIV Infection. NEJM 361: 1768-1775 [Full Text]  
  • Sayer, C, Fisher, M, Nixon, E, Nambiar, K, Richardson, D, Perry, N, Llewellyn, C (2009). Will I? Won't I? Why do men who have sex with men present for post-exposure prophylaxis for sexual exposures?. Sex. Transm. Infect. 85: 206-211 [Abstract] [Full Text]  
  • Zenner, D, Tomkins, S, Charlett, A, Wellings, K, Ncube, F (2009). HIV prone occupational exposures: epidemiology and factors associated with initiation of post-exposure prophylaxis. J. Epidemiol. Community Health 63: 373-378 [Abstract] [Full Text]  
  • Terrazas-Aranda, K., Van Herrewege, Y., Hazuda, D., Lewi, P., Costi, R., Di Santo, R., Cara, A., Vanham, G. (2008). Human Immunodeficiency Virus Type 1 (HIV-1) Integration: a Potential Target for Microbicides To Prevent Cell-Free or Cell-Associated HIV-1 Infection. Antimicrob. Agents Chemother. 52: 2544-2554 [Abstract] [Full Text]  
  • Cohen, M. S., Gay, C., Kashuba, A. D.M., Blower, S., Paxton, L. (2007). Narrative Review: Antiretroviral Therapy to Prevent the Sexual Transmission of HIV-1. ANN INTERN MED 146: 591-601 [Abstract] [Full Text]  
  • Richens, J, Edwards, S G, Sadiq, S T (2005). Can the promotion of post-exposure prophylaxis following sexual exposure to HIV (PEPSE) cause harm?. Sex. Transm. Infect. 81: 190-191 [Full Text]  
  • Van Rompay, K. K. A., Singh, R. P., Pahar, B., Sodora, D. L., Wingfield, C., Lawson, J. R., Marthas, M. L., Bischofberger, N. (2004). CD8+-Cell-Mediated Suppression of Virulent Simian Immunodeficiency Virus during Tenofovir Treatment. J. Virol. 78: 5324-5337 [Abstract] [Full Text]  
  • Pinkerton, S. D., Martin, J. N., Roland, M. E., Katz, M. H., Coates, T. J., Kahn, J. O. (2004). Cost-effectiveness of Postexposure Prophylaxis After Sexual or Injection-Drug Exposure to Human Immunodeficiency Virus. Arch Intern Med 164: 46-54 [Abstract] [Full Text]  
  • De Clercq, E. (2003). Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections. Clin. Microbiol. Rev. 16: 569-596 [Abstract] [Full Text]  
  • Youle, M., Wainberg, M. A. (2003). Pre-Exposure Chemoprophylaxis (PREP) as an HIV Prevention Strategy. J Int Assoc Physicians AIDS Care (Chic Ill) 2: 102-105 [Abstract]  
  • Havens, P. L., Committee on Pediatric AIDS, (2003). Postexposure Prophylaxis in Children and Adolescents for Nonoccupational Exposure to Human Immunodeficiency Virus. Pediatrics 111: 1475-1489 [Abstract] [Full Text]  
  • Gerberding, J. L. (2003). Occupational Exposure to HIV in Health Care Settings. NEJM 348: 826-833 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»